Guggenheim trims Valneva’s price target

A smaller target, same vaccine story

Guggenheim took a fresh look at Valneva SE and nudged its price target down to $11 from $13. That’s not exactly the kind of note that sends confetti flying, but it does keep the market focused on the same thing it always is with Valneva: can the Lyme disease vaccine program turn into a real commercial story?

The guidance part matters, too

The company also reiterated its fiscal 2026 outlook and financial guidance. Translation: management is telling investors, “we haven’t thrown the playbook out the window,” even as the Street recalibrates its expectations.

Why VLA15 is the plot twist

Valneva said the first Phase 3 data readout for VLA15 is expected in the first half of 2026, with regulatory submissions expected to follow through Pfizer if the results come back positive.

For investors, that means the stock’s next major move is likely tied to a binary-ish milestone:

• good data, and the Lyme vaccine thesis gets a lot more credibility
• weak data, and this whole story gets a lot harder to sell

Big picture

So yes, this is just one analyst taking a slightly less sunny view. But for a small-cap biotech with a heavyweight partner like Pfizer in the mix, the real drama is still ahead. The next Phase 3 readout is the main event, and everything else is basically the trailer.